Case-control study
Haptoglobin Gene Expression and Anthracycline-Related Cardiomyopathy in Childhood Cancer Survivors
- Matched case-control study
Authors' conclusion
These findings provide evidence of a novel association between HP2 allele and cardiomyopathy.
Study context
- Population
- Childhood cancer survivors exposed to anthracyclines
- Participants
- 40 vs 64
- Comparison
- Cases vs Control
- Casesn = 40
- Controln = 64reference
- Outcome
- Association between gene expression (differentially expressed genes (DEGs)) and anthracycline-related cardiomyopathy
Main finding
As reported in the abstract
Cardiomyopathy by HP gene expression (HP top DEG)
Odds ratio
6.4
95% CI 1.4–28.6
Higher HP gene expression vs Control
OR 6.4 (95% CI 1.4–28.6)
Observational data: associations, not effects.
Further findings
| Outcome | OR (95% CI) | |
|---|---|---|
| Cardiomyopathy with HP1-2/HP2-2 genotypes plus G/G for rs35283911 and/or rs2000999 | 3.9 (1.0–14.5) | |
| 0.050.21520Odds ratio (log scale) |
Haptoglobin (HP) transcript levels by genotype
- HP2 allele (vs HP1-1, HP1-2, HP2-2 genotypes) and G allele of rs35283911 and rs2000999 had higher HP transcript levels
Original publication
Haptoglobin Gene Expression and Anthracycline-Related Cardiomyopathy in Childhood Cancer Survivors. JACC CardioOncol. Published 7 February 2023. doi:10.1016/j.jaccao.2022.09.009
Summarised from the published abstract; every number is checked against it